Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: Results of a phase 3 randomized double-blind placebo-controlled study Meeting Abstract
| Authors: | Zelenetz, A. D.; Robak, T.; Coiffier, B.; Delgado, J.; Marlton, P.; Adewoye, A. H.; Kim, Y.; Dreiling, L. K.; Hillmen, P. |
| Abstract Title: | Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: Results of a phase 3 randomized double-blind placebo-controlled study |
| Meeting Title: | 57th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 126 |
| Issue: | 23 |
| Meeting Dates: | 2015 Dec 5-8 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2015-12-03 |
| Language: | English |
| ACCESSION: | WOS:000368019000006 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V126.23.LBA-5.LBA-5 |
| Notes: | Meeting Abstract: LBA-5 -- 57th Annual Meeting of the American-Society-of-Hematology -- DEC 05-08, 2015 -- Orlando, FL -- Source: Wos |
